Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ortodermina is a topical local anesthetic formulation containing 5% lidocaine hydrochloride. It is specifically designed to provide symptomatic relief from pain, itching, and burning associated with various skin conditions, including inflammation, minor wounds, and dermatological trauma. As an amide-type local anesthetic, lidocaine works by stabilizing the neuronal membrane through the inhibition of ionic fluxes required for the initiation and conduction of nerve impulses. This is achieved by blocking voltage-gated sodium channels in the neuronal cell membrane. Produced by SOFAR S.p.A., Ortodermina is used in clinical practice for localized wound management and the relief of pruritic or painful skin irritations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ortodermina.